Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Pharming Q3 2026: Strong Growth, Joenja Upside, November Phase II Data Catalyst

Oct 27, 2026, 2:06 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Q3 growth, improved profitability, and a clear near-term data catalyst (Nov Phase II) plus expansion milestones for Joenja likely to lift sentiment; a tighter but higher-end full-year guide signals discipline with upside risk.

AI summary

What happened, with direct paths to the underlying reporting

Pharming reported Q3 2026 revenue of $117.6M, up 21% year over year, led by RUCONEST and Joenja. The company tightened 2026 guidance to $380–$390M, while operating profit surged 89% to $29.9M and cash flow from operations reached $32.4M for the quarter, lifting cash to $190.9M. Positive Phase II leniolisib topline data for genetic PIDs with immune dysregulation, and broader CVID data due in November 2026, present near-term catalysts amid ongoing Joenja expansion (US pediatric label, Germany and Japan).

Pharming Q3 2026 revenue up 21% to $117.6M; RUCONEST and Joenja driving growth.
Joenja revenue up 58% to $23.8M; strong U.S. and international demand.
2026 revenue guidance tightened to $380–$390M; operating profit up 89% to $29.9M.
Phase II leniolisib data in genetic PIDs with immune dysregulation due Nov 2026; CVID data also expected.
Cash flow from ops $32.4M; cash balance $190.9M; Joenja expansion progressing (US pediatric label, Germany/Japan).

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.